Achillion to Present at the Leerink Partners Roundtable Series
September 25 2018 - 6:00AM
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN)
announced today that Joseph Truitt, President and Chief Executive
Officer of Achillion, will present at the Leerink Partners
Roundtable Series: Rare Disease & Oncology on Tuesday, October
2, 2018, at 8:00 a.m. ET at the Lotte New York Palace, New York,
NY.
The live audio and subsequent archived webcasts
of the Company's presentations will be accessible from the
Company's investor relations website, http://ir.achillion.com. The
audio recording will be archived for 30 days following the live
presentation. Please connect to Achillion's website several minutes
prior to the start of the presentation to ensure adequate time for
any software downloads that may be necessary.
About Achillion
Pharmaceuticals
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) is
a clinical-stage biopharmaceutical company focused on
advancing its oral factor D inhibitors into late-stage
development and commercialization. Each of the drug candidates
in the Company’s oral factor D portfolio was discovered in its
laboratories and is wholly owned. Achillion is focusing its
drug development activities on alternative pathway-mediated rare
diseases where there are no approved therapies or where existing
therapies are inadequate for patients. To advance its
investigational drugs into phase 3 and commercialization, the
Company plans to work closely with key stakeholders including
patients, payors, regulators and healthcare professionals.
More information is available at http://www.achillion.com.
Investors & Media:Brian
DiDonatoVice President, Investor Relations and Corporate
CommunicationsAchillion Pharmaceuticals, Inc.Tel. (215) 709-3032
bdidonato@achillion.com
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From Apr 2024 to May 2024
Achillion Pharmaceuticals (NASDAQ:ACHN)
Historical Stock Chart
From May 2023 to May 2024